From diagnosis methods to management of comorbid infections, new lung cancer protocols adaptable for various conditions ...

Compassionate-use lurbinectedin demonstrates modest yet consistent efficacy and is well tolerated in patients with ...

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

The age-adjusted cancer death rate has fallen since the 1990s, with the world winning the so-called "war on cancer." ...

A Flinders University study shows that bowel cancer survivors face an elevated risk of developing multiple primary cancers ...

They want to gain a deeper understanding of why the disease behaves differently in these patients. Read more at ...

Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54% Strong efficacy signal observed in non-squamous ...

Stock image by PDPics from PixabayA Flinders University study shows that bowel cancer survivors face an elevated risk of ...

Small cell lung cancer (SCLC), one of the deadliest types of lung cancer, is an aggressive tumor that metastasizes early ...

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

Researchers engineered a nanobody-conjugated liposome (A5-LNP-DOX) that targets CD155 and delivers doxorubicin directly to lung adenocarcinoma cells, dramatically suppressing tumor growth in ...